Prospective trial to identify optimal bladder cancer surveillance protocol: Reducing costs while maximizing sensitivity

BJU International

Volumn 108, Issue 7, 2011, Pages 1119-1123

  Kamat, Ashish M ^a   Karam, Jose A ^a   Grossman, H Barton ^a   Kader, A Karim ^b   Munsell, Mark ^a   Dinney, Colin P ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

bladder cancer; cost effectiveness; surveillance

Indexed keywords

BIOLOGICAL MARKER; NUCLEAR MATRIX PROTEIN 22; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INVASION; CANCER RECURRENCE; CLINICAL PROTOCOL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; CYSTOSCOPY; CYTODIAGNOSIS; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROSPECTIVE STUDY; SENSITIVITY ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CLINICAL PROTOCOLS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 80052391828     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.10026.x     Document Type: Article

References (19)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics. CA Cancer J Clin 2009; 59: 225-49
2. Kaufman DS, Shipley WU, Feldman AS,. Bladder cancer. Lancet 2009; 374: 239-49
3. Rubben H, Lutzeyer W, Fischer N, Deutz F, Lagrange W, Giani G,. Natural history and treatment of low and high risk superficial bladder tumors. J Urol 1988; 139: 283-5
4. Raghavan D, Shipley WU, Garnick MB, Russell PJ, Richie JP,. Biology and management of bladder cancer. N Engl J Med 1990; 322: 1129-38 (Pubitemid 20149531)
5. Horner MJ, Krapcho M, Neyman N, et al,. SEER cancer statistics review, 1975-2006, national cancer institute. Available at:. Accessed December 24 2009
6. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R,. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003; 21: 1315-30 (Pubitemid 38041357)
7. van Rhijn BWG, van der Poel HG, van der Kwast TH,. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 2005; 47: 736-48 (Pubitemid 40745338)
8. Grossman HB, Messing E, Soloway M, et al,. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 2005; 293: 810-6 (Pubitemid 40250364)
9. Zippe C, Pandrangi L, Potts JM, Kursh E, Novick A, Agarwal A,. NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer. Anticancer Res 1999; 19: 2621-3 (Pubitemid 29392423)
10. Grossman HB, Soloway M, Messing E, et al,. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 2006; 295: 299-305 (Pubitemid 43112958)
11. Varella-Garcia M, Akduman B, Sunpaweravong P, Di Maria MV, Crawford ED,. The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer. Urol Oncol: Semin Orig Investig 2004; 22: 16-9 (Pubitemid 38542707)
12. Laila Dahmoush MBC,. FISHing and beyond in urinary cytology. Diagn Cytopathol 2004; 31: 201-3
13. Sarosdy MF, Schellhammer P, Bokinsky G, et al,. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 2002; 168: 1950-4
14. The United Kingdom and Eire Bladder Tumour Antigen Study Group. The use of the bladder-tumour associated analyte test to determine the type of cystoscopy in the follow-up of patients with bladder cancer. Br J Urol 1997; 79: 362-6
15. Lachaine J, Valiquette L, Crott R,. Economic evaluation of NMP22 in the management of bladder cancer. Can J Urol 2000; 7: 974-80
16. Lotan Y, Roehrborn CG,. Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach. J Urol 2002; 167: 75-9 (Pubitemid 34024503)
17. Nam RK, Redelmeier DA, Spiess PE, Sampson HA, Fradet Y, Jewett MA,. Comparison of molecular and conventional strategies for followup of superficial bladder cancer using decision analysis. J Urol 2000; 163: 752-7 (Pubitemid 30091609)
18. van der Aa MN, Zwarthoff EC, Steyerberg EW, et al,. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]). Eur Urol 2009; 55: 659-67
19. Hedelin H, Holmang S, Wiman L,. The cost of bladder tumour treatment and follow-up. Scand J Urol Nephrol 2002; 36: 344-7 (Pubitemid 35373621)